Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week…
- Trial name
- DreaMS (NCT01226745)
- Testing
- ONO-4641
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 340 people
- Sponsor
- EMD Serono
Intrathecal Baclofen, Multiple Sclerosis
Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study
The methodology is a feasibility study to determine the feasibility of assessing people in the community with a neurological condition before proceeding towards a full powered community trial evaluating the influence of…
- Conditions
- Intrathecal Baclofen, Multiple Sclerosis, Respiratory System, Cerebral Palsy
- Trial name
- NCT03151941
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Solent NHS Trust
Multiple Sclerosis, Fatigue
Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
Fatigue is a common symptom in multiple sclerosis (MS) that is characterized by physical and/or mental exhaustion. Fatigue is difficult to treat and treatment efficacy of available therapy is limited.
- Trial name
- MS (NCT01879202)
- Testing
- Methylphenidate modified release, Maltodextrin
- Where
- Austria
- Volunteers
- 96 people
- Sponsor
- Medical University of Vienna
Multiple Sclerosis
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
- Trial name
- NCT00915577
- Testing
- Interferon beta-1a, Single-use autoinjector
- Volunteers
- 74 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Neuromyelitis Optica Spectrum Disorders (NMOSD)
BLAZE-Limiting Approach in NMOSD
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).
- Trial name
- NCT06888622
- Testing
- Eculizumab administration
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Huashan Hospital
Demyelinating Diseases, Demyelination; Corpus Callosum
Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with acute inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive
- Trial name
- ReINFORCE (NCT06065670)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Home Exercise Telerehabiliation for MS
The primary purpose of this study is to evaluate the effects of an individualized telerehabilitation program on mobility, fatigue, and quality of life for Veterans with MS.
- Trial name
- NCT03655431
- Testing
- Telerehabilitation, Standard treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shane.Chanpimol
Multiple Sclerosis, Fatigue
Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial
The purpose of this study was to test the feasibility and effectiveness of a novel exercise intervention for individuals who live with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Fatigue, Balance, Dizziness
- Trial name
- NCT01216137
- Testing
- Exercise: Vestibular Rehabilitation, Exercise
- Volunteers
- 38 people
- Sponsor
- University of Colorado, Denver
Relapsing-remitting Multiple Sclerosis
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.
- Trial name
- Biobank (NCT01310166)
- Testing
- Fingolimod
- Where
- 61 sites in Germany
- Volunteers
- 447 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Malignant Tumor
Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase
Even though the therapeutic panel for multiple sclerosis (MS) treatment has improved in the last 20 years, safety data especially for the second-line and innovative treatments are lacking.
- Trial name
- PVSEPK (NCT04237337)
- Testing
- Exposure to MS drugs
- Volunteers
- 200,000 people
- Sponsor
- University Hospital, Caen
Multiple Sclerosis
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
The Departments of Neurology and Neurosurgery are conducting this research study to evaluate the safety and effectiveness of intravascular angioplasty for the treatment of venous narrowing in the treatment of Multiple Sclerosis…
- Trial name
- PREMiSE (NCT01450072)
- Testing
- Selective Venography followed by therapeutic balloon angioplasty, Control arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body.
- Trial name
- EXO-MOBILITY (NCT07252895)
- Testing
- EXOPULSE Suit in Active mode
- Where
- 11 sites in France
- Volunteers
- 77 people
- Sponsor
- Otto Bock France SNC
Multiple Sclerosis, Ataxia
"Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis"
Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide,1 it is a degenerative disease that selectively affects the central…
- Conditions
- Multiple Sclerosis, Ataxia, Paraplegia
- Trial name
- EXO (NCT05563402)
- Testing
- Atalante
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Multiple Sclerosis Center of Catalonia
Multiple Sclerosis, Fatigue
Telephone-Delivered Exercise for Multiple Sclerosis Fatigue
Multiple sclerosis (MS) is a progressive demyelinating disorder that damages white matter in the central nervous system. Although individuals experience mobility (e.g., walking, balance) impairments that lower quality of life and…
- Conditions
- Multiple Sclerosis, Fatigue, Physical Activity
- Trial name
- NCT03256851
- Testing
- Telephone-Delivered Exercise Therapy, In-Person Delivered Exercise Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wayne State University
Multiple Sclerosis
Effect of High-Intensity Focused Electromagnetic Therapy on Balance and Quality of Life in Patients With Multiple Sclerosis
Evaluate the effect of High-Intensity Focused Electromagnetic Therapy on dynamic balance, fall risk, core muscle function, and quality of life in patients with multiple sclerosis.
- Trial name
- NCT07646912
- Testing
- High-Intensity Focused Electromagnetic Therapy, Balance Exercises
- Volunteers
- 60 people
- Sponsor
- Middle East University
Multiple Sclerosis
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
The greatest unmet need for people with multiple sclerosis is an effective therapy for the progressive phase. Current treatments suppress the damage caused by the immune system but there is only a limited window in which these…
- Trial name
- NCT05131828
- Testing
- Metformin and clemastine in combination
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Multiple Sclerosis
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
The primary outcome of the study is to evaluate the cumulative area under the concentration time curve (AUC) over 2 weeks, as measured by AUC from time 0 to 336 hours post dose (AUC0-336h), for serum concentrations of BIIB017 and…
- Trial name
- NCT02269930
- Testing
- peginterferon beta-1a, Rebif
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Cognitive Impairment
Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis
This study is a cross sectional study of patients diagnosed with clinically isolated syndrome (CIS) and RRMS, who will undergo a series of tests to assess cognitive impairment, fatigue severity and depressive symptoms.
- Trial name
- NCT01250665
- Where
- Switzerland
- Volunteers
- 65 people
- Sponsor
- Cantonal Hospital of St. Gallen
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.